Research and practice in thrombosis and haemostasis · 2025
Identification of novel gene expression programs in thrombin-stimulated hepatic stellate cells.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mac Noah A, Prasad Sia, Capece Gina E, Martínez-Zamudio Ricardo Iván, McClenaghan Conor, Poole Lauren G
Аннотация
BACKGROUND: Evidence suggests that the coagulation factor thrombin plays a pathologic role in liver fibrosis. Studies have proposed that thrombin signaling through protease-activated receptor-1 (PAR1) promotes activation of hepatic stellate cells (HSCs), the primary collagen-producing cells in the fibrotic liver. However, a comprehensive view of the effect of thrombin on HSCs is lacking.
OBJECTIVES: This study tests the hypothesis that thrombin induces expression of fibrogenic mediators in HSCs via PAR1 activation.
METHODS: Immortalized human HSCs (LX-2) were cultured for 48 hours, then stimulated with human α-thrombin (0-10 U/mL). In some experiments, cells were pretreated with the PAR1 antagonist, vorapaxar (0.01-10 μM). PAR1 activation and gene and protein expression were assessed.
RESULTS: Rapid intracellular calcium mobilization was detected in thrombin-stimulated HSCs (0-10 U/mL) in a dose-dependent manner, which was blocked by vorapaxar pretreatment. Surprisingly, HSCs treated with thrombin for 24 to 48 hours did not affect gene or protein expression of fibrotic mediators. However, thrombin treatment for 4, 24, or 48 hours did provoke distinct transcriptomic changes. Pathway overrepresentation analysis revealed altered pathways associated with cell migration, inflammation, and metabolism, as well as enrichment for published gene signatures associated with HSC activation. Interestingly, several genes from altered pathways were shown to be regulated by PAR1 signaling.
CONCLUSION: These results show that thrombin alters previously unidentified transcriptomic profiles, suggesting a program toward HSC activation. Thrombin activates complex signaling pathways for HSC preinitiation, which may drive HSC activation and hepatic fibrosis.
OBJECTIVES: This study tests the hypothesis that thrombin induces expression of fibrogenic mediators in HSCs via PAR1 activation.
METHODS: Immortalized human HSCs (LX-2) were cultured for 48 hours, then stimulated with human α-thrombin (0-10 U/mL). In some experiments, cells were pretreated with the PAR1 antagonist, vorapaxar (0.01-10 μM). PAR1 activation and gene and protein expression were assessed.
RESULTS: Rapid intracellular calcium mobilization was detected in thrombin-stimulated HSCs (0-10 U/mL) in a dose-dependent manner, which was blocked by vorapaxar pretreatment. Surprisingly, HSCs treated with thrombin for 24 to 48 hours did not affect gene or protein expression of fibrotic mediators. However, thrombin treatment for 4, 24, or 48 hours did provoke distinct transcriptomic changes. Pathway overrepresentation analysis revealed altered pathways associated with cell migration, inflammation, and metabolism, as well as enrichment for published gene signatures associated with HSC activation. Interestingly, several genes from altered pathways were shown to be regulated by PAR1 signaling.
CONCLUSION: These results show that thrombin alters previously unidentified transcriptomic profiles, suggesting a program toward HSC activation. Thrombin activates complex signaling pathways for HSC preinitiation, which may drive HSC activation and hepatic fibrosis.